" class="no-js "lang="en-US"> Vir Biotechnology - Medtech Alert
Saturday, August 02, 2025
Vir Biotechnology | Pharmtech Focus

Vir Biotechnology

About Vir Biotechnology

Vir Biotechnology

We were founded with the mission of creating a world without infectious disease.

We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and the cause of hundreds of billions of dollars of economic burden each year. We believe that now is the time to apply the recent and remarkable advances in immunology to combat infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.

We are taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions.

We have an industry-leading management team, board of directors and scientific advisors with significant experience in immunology and infectious diseases, and with progressing product candidates from early stage research to clinical trials, regulatory approval and ultimately commercialization.

Guided by science, we relentlessly build on our immunologic expertise and technologies in pursuit of transformative medicines for infectious diseases. Our innovations stem from courage and bold ideas. We approach each day with a sense of optimism and humility, recognizing that our strength resides in the diversity of our journeys and the opportunity to learn from each other.

Related Story

GSK and VIR Biotechnology EMA Rolling Review of VIR-7831 (Sotrovimab)

May 7 2021

GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency (EMA) has […]

Lilly, Vir, GSK Announce Positive Topline Data from Phase 2 BLAZE-4 Trial

March 30 2021

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced […]